Advanced Materials IP Licensing Platform
Four patent families spanning targeted drug delivery, real-time oxygen sensing, industrial carbon capture, and next-generation satellite materials. Cisplatin-validated. Ready for licensing.
About the Platform
Metal-organic frameworks are crystalline, porous materials with unparalleled tunability. We have built a portfolio of four interlocking patent families — each targeting a distinct, high-value industry — all sharing the same foundational MOF science.
Licenses may be structured as single-family, multi-family, or full portfolio. All families are available for exclusive, co-exclusive, or non-exclusive arrangements. Full characterization data, synthesis protocols, and in vitro cell data available under NDA.
Patent Portfolio
Azobenzene-based MOF platform triggers drug release exclusively in hypoxic tumor microenvironments via azo-bond reductive cleavage. Cisplatin-validated with 44–47% drug loading and up to 89% encapsulation efficiency. PXRD confirms structural collapse onset at 1 hour under hypoxia; full stability under normoxia.
Phosphorescent Cu(I) complexes and pyridylimine-functionalized MOFs detect intratumoral oxygen tension in real time via phosphorescence quenching. Up to 85% quenching within 20 minutes. Liposome-MOF conjugate system enables closed-loop theranostics — simultaneous tumor mapping and triggered drug release from a single construct.
Six MOF formula families — imidazolate ZIFs, amino-functionalized frameworks, MOF-74 DOBDC series, mixed-metal MOFs, transition metal organometallics, and N-heterocyclic carbene complexes — targeting CO₂ capture from power generation, cement, steel, refinery, and chemical manufacturing sources.
Five MOF formula families engineered for extreme space environments: lanthanide-based (Gd/Hf) for neutron and gamma-ray shielding, Zr-based UiO series for thermal stability to 500°C, Zn-MOFs for lightweight gas storage, iron/chromium porphyrin MOFs for catalysis, and ZIFs for CO₂ scrubbing in manned missions.
Validated Proof of Concept
Experimental Data
Cisplatin (MW 300.05, Cl₂H₆N₂Pt) loaded at 37°C, 200 RPM, 48 hr incubation. Analysis by UV-Vis spectroscopy.
| Sample | Encapsulated | DL % | EE % |
|---|---|---|---|
| Sample 1 | 3.91 mg | 43.87% | 78.15% |
| Sample 2 | 4.43 mg | 46.99% | 88.66% |
| Sample 3 | 4.38 mg | 46.71% | 87.65% |
| Timepoint | Normoxia | Hypoxia | Fold Δ |
|---|---|---|---|
| 30 min | 0.175 mg | 1.537 mg | 8.8× |
| 2 hr | 0.356 mg | 2.626 mg | 7.4× |
| 24 hr | 0.965 mg | 4.117 mg | 4.3× |
| 72 hr | 2.306 mg | 5.422 mg | 2.4× |
Development Stage
All four families are available for licensing now. Drug delivery and oxygen sensing have the deepest data packages; carbon capture and satellite are IP-stage with compelling structural frameworks.
◆ TEAL = active / complete · ◆ GOLD = near-term / in progress · ○ OUTLINE = planned
Licensing
Every licensing structure is negotiable. We can accommodate single-family, multi-family, or full portfolio deals across any geography and field of use.
Single licensee per field of use. Upfront fee + milestone payments + royalty on net sales. Full technical support from inventors included.
Up to two licensees sharing rights across defined indication areas or geographies. Preferred for multi-indication platforms.
Field-of-use restricted access for multiple partners. Ideal for platform technologies being deployed across distinct verticals (e.g., oncology + industrial CCS).
Time-limited exclusivity window for diligence, feasibility studies, and IND-enabling work before committing to full license terms.
Get in Touch
Full synthesis protocols, characterisation data, and cisplatin cell results available under NDA. Complete the form and we'll respond within 48 hours.